Menu
Menu
We spoke with Dr. Cristovam Scapulatempo Neto, Medical Director of Pathology and Genomics and Technical Director at DASA, Latin America’s largest integrated health network serving more than 300,000 patients each day.
2026 marks a significant milestone: DASA and SOPHiA GENETICS celebrated 10 years of partnership – a decade defined by shared ambition, scientific collaboration, and a relentless commitment to advancing precision oncology research at scale.
In this spotlight, Dr. Scapulatempo Neto shares how DASA’s collaboration with SOPHiA GENETICS has evolved into a trusted, longstanding partnership – one that is accelerating innovation and expanding access to advanced technologies like SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution and MSK-ACCESS® powered with SOPHiA DDM™.
Below, he reflects on the unique aspects of the partnership, the impact achieved so far, and how new applications are helping DASA expand their impact across Brazil.
Watch the spotlight:
“SOPHiA GENETICS listens to us and helps us challenge the status quo by bringing what we need to the market, especially in the development of new applications.”
Could you introduce yourself and your work at DASA?
My name is Cristovam Scapulatempo Neto. I’m a pathologist by training, Medical Director of Pathology and Genomics here at DASA, and also the Technical Director for Dasa across all of Brazil.
What makes the collaboration between DASA and SOPHiA GENETICS unique?
I think the partnership with SOPHiA GENETICS has been very successful. I've always said we are much more than partners. SOPHiA GENETICS listens to us and helps us challenge the status quo by bringing what we need to the market, especially in the development of new applications.
Together, we were able to co-develop applications that have truly transformed the market. Take HRD, for instance – we were among the first labs in the world to implement the test, besides the original lab that developed it. This has brought significant benefits to thousands of patients, not only in Brazil but worldwide.
“We’re still in the ramp-up phase, yet our turnaround time is short, and the results we’re seeing at this stage are spectacular.”
How did working with SOPHiA GENETICS lead you to adopt MSK-ACCESS® powered with SOPHiA DDM™?
Liquid biopsy is a fantastic technology. I believe it’s the only solution on the market that sequences both genomic DNA and tumor DNA. This allows us to differentiate variants and mutations, whether they are germline, somatic, or CHIP (clonal hematopoiesis of indeterminate potential). I don’t think any other commercial solution provides this.
We’re still in the ramp-up phase, yet our turnaround time is short, and the results we’re seeing at this stage are spectacular.
We’re now expanding the use of this biopsy solution to both cerebrospinal fluid and cavity fluids, which will allow us to test patients with less invasive procedures, especially those with brain metastases. Today, the market offers very few options for these patients.
Discover how SOPHiA DDM™ supports advanced tumor analysis
Connect with our team to discover how SOPHiA DDM™ for Solid Tumors and Liquid Biopsy can deliver fast, scalable, and accurate molecular analysis and insights. Request a demo to see our fully integrated analytical, interpretation, and reporting capabilities in action.
SOPHiA GENETICS products are for Research Use Only (RUO) and not for use in diagnostic procedures, unless specified otherwise.
The opinions expressed during the video are those of the speaker and may not represent the opinions of SOPHiA GENETICS. Any use of SOPHiA GENETICS products described in the video may not have been cleared or approved by Regulatory Authorities. MSK-ACCESS® powered with SOPHiA DDM™ has been internally verified for use with blood samples only. No internal verification has been performed for any other sample types.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
